On this page
De novo classification applies when no legally marketed predicate device exists; the device is evaluated on its own merits and classified into Class I or II. The 510(k) pathway applies when a predicate device exists; the manufacturer must demonstrate substantial equivalence to that device. The choice is not discretionary, it is determined by predicate device availability.
- A device without a legally marketed predicate must pursue de novo classification; without it, devices first marketed after May 28, 1976 default to Class III.
- De novo classification requires the manufacturer to prove safety and effectiveness through general controls alone or general and special controls, with a median timeline of 319 calendar days from receipt [F10, F12].
- The 510(k) pathway requires comparison to one or more predicate devices and demonstration of substantial equivalence, typically resolved within 90 days [F13, F17].
- Devices successfully classified through de novo can themselves become predicates for future 510(k) submissions.
- De novo requests incur an FDA fee of $191,020 as of October 1, 2026, while 510(k) submissions have different fee structures.
The FDA regulates medical devices through premarket review pathways that determine which devices reach the market and under what conditions. Two pathways dominate: de novo classification and 510(k) clearance. They are not interchangeable options a manufacturer can choose between. Instead, the availability of a legally marketed predicate device determines which pathway applies. Understanding this distinction matters for device manufacturers planning market entry, investors evaluating device companies, and analysts assessing the regulatory burden a company faces. The choice of pathway shapes the evidence required, the timeline to decision, and the regulatory classification the device receives.
When the FDA uses de novo classification vs 510(k) clearance
The FDA's choice between these pathways hinges on a single criterion: whether a legally marketed device of the same type already exists. If one does, the 510(k) pathway applies. If none exists, de novo classification is required. This distinction has profound consequences. A device pursuing de novo must establish its own safety and effectiveness profile from the ground up. A device pursuing 510(k) must demonstrate that it is substantially equivalent to an existing device, a different and typically less demanding evidentiary standard. The pathway determines not only the evidence the manufacturer must gather but also the timeline to clearance, the regulatory classification the device receives, and whether future similar devices can reference it as a predicate. For companies, this is not a strategic choice but a regulatory fact determined by what has come before.
The predicate device requirement
A predicate device is the legal anchor of the 510(k) pathway. Under Section 513(i) of the FD&C Act, a device qualifies as substantially equivalent if it has the same intended use as the predicate device and meets equivalence criteria established by the FDA. A legally marketed device that can serve as a predicate includes a device that was legally marketed prior to May 28, 1976, a device that has been cleared through the 510(k) process, or a device granted marketing authorization via de novo classification. The predicate must be chosen carefully. FDA guidance recommends selecting a predicate device that was cleared using well-established methods, meets or exceeds expected safety and performance, is without unmitigated use-related or design-related safety issues, and is without an associated design-related recall. Without a predicate, a manufacturer cannot pursue 510(k) clearance. By law, a device first marketed after May 28, 1976 is placed in Class III by default unless it is substantially equivalent to a classified device, is reclassified, or is classified through a de novo request. This default classification into the highest regulatory class creates a powerful incentive to find a predicate if one exists.
De novo classification pathway
De novo classification is a pathway for novel medical devices that do not have a predicate device and can be classified into Class I or II. The FDA evaluates whether general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use. The pathway exists precisely because some devices are genuinely novel, they do not fit the profile of any existing device, and forcing them into the default Class III category would be inappropriate. De novo requests can be submitted in two ways. Option 1 follows a high-level not substantially equivalent determination in response to a 510(k) submission, the manufacturer tried to find a predicate, could not establish substantial equivalence, and now seeks de novo classification. Option 2 is direct: upon the requester's determination that no legally marketed device exists upon which to base substantial equivalence, the manufacturer submits de novo without first attempting 510(k).
When de novo applies
De novo applies when no legally marketed predicate device exists for the intended use and technological characteristics of the device. This occurs most often with genuinely novel devices, those that represent a new approach to diagnosis, monitoring, or treatment, or that use technological methods not previously cleared for that use. De novo also applies when a manufacturer has submitted a 510(k) and received a high-level not substantially equivalent determination.
Regulatory outcome of de novo classification
A successful de novo classification results in the device being placed into Class I or II rather than defaulting to Class III. This classification determination is binding and establishes the regulatory requirements for that device type going forward. Critically, devices classified through a de novo request may be marketed and used as predicates for future 510(k) submissions, when applicable. This transforms the first-to-market device into a regulatory anchor for competitors. Subsequent manufacturers can reference the de novo-classified device as a predicate, potentially using the faster 510(k) pathway instead of pursuing their own de novo classification.
510(k) clearance pathway
The 510(k) pathway is a premarket notification process in which a manufacturer submits information about the device's intended use, design, and performance characteristics compared to a predicate device. The manufacturer must compare the device to one or more similar legally marketed devices and make and support substantial equivalence claims. Substantial equivalence means the device has the same intended use as the predicate device and is demonstrated to be as safe and effective as the legally marketed device. The 510(k) pathway is faster and less data-intensive than de novo because the predicate device already has an established safety and effectiveness profile. The manufacturer does not need to prove absolute safety and effectiveness; it needs to show that its device performs comparably to the predicate on the dimensions that matter for that use.
When 510(k) applies
The 510(k) pathway applies when a legally marketed predicate device exists. The manufacturer must be able to identify at least one device already on the market that serves the same intended use and can serve as a valid comparison point. If such a device exists, the manufacturer may pursue 510(k) rather than de novo. The pathway is available regardless of whether the device uses novel technology, as long as the intended use matches an existing predicate. A device with cutting-edge technology can still use 510(k) if its intended use is the same as a predicate device and the manufacturer can support substantial equivalence.
Types of 510(k) submissions
The 510(k) pathway has a core requirement of comparison to a predicate device. 510(k) submissions include comparative data on safety and effectiveness. Certain device categories may qualify for streamlined review under specific FDA programs. The distinction between these variants affects the scope of data required and sometimes the review timeline, but all require predicate device comparison and all are subject to the same fundamental standard: substantial equivalence to a legally marketed device.
Direct comparison: de novo vs 510(k) on key criteria
The two pathways differ systematically across the dimensions that matter most to manufacturers and market analysts. The table below presents these differences side by side.
The most consequential difference is the evidence burden. De novo requires the manufacturer to establish a complete safety and effectiveness profile. The 510(k) pathway leverages the predicate device's existing profile and requires only comparative data. This difference drives the timeline: 510(k) submissions typically resolve faster because the predicate device's regulatory history provides a foundation. De novo submissions take longer because the FDA is evaluating a device type for the first time.
Implications for device manufacturers and market entry
For a device manufacturer, the pathway determination shapes the entire regulatory strategy. A manufacturer of a truly novel device faces de novo classification as a requirement, not a choice. The pathway requires substantial upfront investment in safety and effectiveness data, a longer timeline to market, and significant FDA user fees. However, successful de novo classification places the device in Class I or II rather than the default Class III, potentially reducing post-market regulatory burden. The de novo-classified device also becomes a predicate for competitors, which can be strategically valuable if the company plans to develop follow-on variants.
A manufacturer with a device that fits an existing predicate category can pursue 510(k) clearance, which typically resolves faster and requires less comprehensive data generation. The predicate device provides a regulatory anchor; the manufacturer's task is to demonstrate that its device is comparable on the dimensions that matter. This pathway is accessible to companies with smaller regulatory budgets and shorter timelines to market.
For market analysts evaluating device companies, the pathway determines the regulatory timeline and cost structure. A company bringing a de novo device to market should be modeled with a longer pre-revenue period and higher regulatory spending. A company pursuing 510(k) clearance faces a shorter, more predictable timeline. The choice of pathway also signals something about the device's market positioning: de novo devices are novel and may command premium pricing or market share if they address an unmet need; 510(k) devices are typically incremental improvements or alternatives to existing solutions, competing partly on regulatory efficiency.
Do this automatically
Determining whether a device requires de novo classification or 510(k) clearance involves reviewing predicate device databases, conducting substantial equivalence analyses, and preparing the appropriate submission, a manual process that regulatory teams repeat for each new device or indication. Software tools can automate predicate device searches, flag regulatory pathways based on device characteristics, and organize submission documentation to reduce the time spent on these repetitive classification tasks. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
